安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- FDA approves fruquintinib in refractory metastatic colorectal . . .
On November 8, 2023, the Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc ) for adult patients with metastatic colorectal cancer (mCRC) who received prior
- Treatment for KRAS G12C-mutated metastatic CRC approved by FDA
The U S Food and Drug Administration has approved sotorasib in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer
- FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH . . .
In June 2017, the FDA approved a refined indication for Vectibix for use in patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) mCRC, specifically as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with
- New colorectal cancer treatment approved in the U. S. - Takeda
Takeda announces the FDA has approved a new treatment for adults with previously treated metastatic Colorectal Cancer (mCRC)
- FDA Approval Summary: Fruquintinib for the Treatment of . . .
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, −2, and −3, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA . . . - Merck
KEYTRUDA and KEYTRUDA QLEX are each indicated for the treatment of adult patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test
- FDA Approves Sotorasib Plus Panitumumab for KRAS G12C-Mutated . . .
The approval of this treatment could mark a new standard of care for patients with KRAS G12C–mutated metastatic CRC, as the treatment was able to provide longer PFS and improve disease control
- The FDA Approves Sotorasib With Panitumumab for Treatment of . . .
CRC is the third leading cause of cancer-related mortality in the United States, accounting for approximately 11% of all diagnoses Although survival outcomes in earlier stages of disease are favorable, those with metastatic disease or mutations have significantly worse outcomes KRAS G12C mutations occurs in an estimated 3% to 4% of patients with mCRC and are among the most common genetic
|
|
|